Hippopotamus

Hippo Premium Packaging Honored with Prestigious Pac Global Packaging Award

Retrieved on: 
Wednesday, February 7, 2024
Partnership, SAN, Hippopotamus, Creativity, Trust, Drink

SAN DIEGO, Feb. 7, 2024 /PRNewswire/ -- Hippo Premium Packaging (www.hippopackaging.com), a leading provider of innovative and sustainable packaging solutions, is thrilled to announce that they have been awarded a prestigious Pac Global Packaging Award for their outstanding work with Maison Bloom, a trailblazing infused beverage company. The award recognizes Hippo's commitment to excellence in packaging design and its significant contribution to the success of Maison Bloom. Hippo won the "Best in Class" award in the "Brand Marketing, New Brand, Beverage" category.

Key Points: 
  • SAN DIEGO, Feb. 7, 2024 /PRNewswire/ -- Hippo Premium Packaging ( www.hippopackaging.com ), a leading provider of innovative and sustainable packaging solutions, is thrilled to announce that they have been awarded a prestigious Pac Global Packaging Award for their outstanding work with Maison Bloom, a trailblazing infused beverage company.
  • The Pac Global Packaging Awards are a globally recognized accolade, celebrating the best in packaging design and innovation.
  • This Pac Global Packaging Award is a testament to the incredible partnership we've built with Hippo."
  • Kary Radestock, Founder and CEO of Hippo Premium Packaging, shared her excitement about receiving the Pac Global Packaging Award, saying, "We are honored to be recognized by Pac Global for our work with Maison Bloom.

AM Best Affirms Credit Ratings of Members of Spinnaker Insurance Group

Retrieved on: 
Tuesday, December 19, 2023
Professional Services, Insurance, Finance, Depreciation, Credit, Hippopotamus, AM Best, Spinnaker, News, Risk management, ALL

AM Best has affirmed the Financial Strength Rating of A- (Excellent) and the Long-Term Issuer Credit Ratings of “a-” (Excellent) of Spinnaker Insurance Company and its 100% reinsured subsidiaries, Spinnaker Specialty Insurance Company and Mainsail Insurance Company, collectively referred to as Spinnaker Insurance Group (Spinnaker).

Key Points: 
  • AM Best has affirmed the Financial Strength Rating of A- (Excellent) and the Long-Term Issuer Credit Ratings of “a-” (Excellent) of Spinnaker Insurance Company and its 100% reinsured subsidiaries, Spinnaker Specialty Insurance Company and Mainsail Insurance Company, collectively referred to as Spinnaker Insurance Group (Spinnaker).
  • The outlook of these Credit Ratings (ratings) is stable.
  • For additional information regarding the use and limitations of Credit Rating opinions, please view Guide to Best's Credit Ratings .
  • For information on the proper use of Best’s Credit Ratings, Best’s Performance Assessments, Best’s Preliminary Credit Assessments and AM Best press releases, please view Guide to Proper Use of Best’s Ratings & Assessments .

Axis Names Cliff Gallant Head of Investor Relations and Corporate Development

Retrieved on: 
Monday, December 18, 2023
Professional Services, Insurance, Finance, AXS, Sale, Corporation, Hippo (company), NYSE, Senior, Head, Portfolio manager, Hippopotamus, Running, National General Insurance, AXIS, Keefe, Bruyette & Woods, Corporate development, Nomura, Allstate

AXIS Capital Holdings Limited (“AXIS Capital” or “AXIS” or the “Company”) (NYSE: AXS), today announced that it has appointed Cliff Gallant as Head of Investor Relations and Corporate Development, effective December 18, 2023.

Key Points: 
  • AXIS Capital Holdings Limited (“AXIS Capital” or “AXIS” or the “Company”) (NYSE: AXS), today announced that it has appointed Cliff Gallant as Head of Investor Relations and Corporate Development, effective December 18, 2023.
  • Mr. Gallant will report to AXIS Chief Financial Officer Peter Vogt and will serve as a member of the Company’s Global Finance leadership team.
  • “His leadership will be invaluable as we continue to deepen engagement within the investment community and foster understanding of our vision and strategy, all as we further elevate AXIS as a specialty leader.”
    Mr. Gallant most recently served as Vice President of Investor Relations and Corporate Development at Hippo Insurance where he built the organization’s investor relations program.
  • Previously Mr. Gallant served as Senior Vice President of Investor Relations at National General Insurance prior to its sale to Allstate, where he then joined the Company’s Corporate Development team.

Q'Apel Medical Inc. Launches "Hippo" The New Generation Aspiration System for Stroke Thrombectomy

Retrieved on: 
Tuesday, December 12, 2023
DNA, Prisma Health, Patient, Thrombectomy, FDA, Baylor College of Medicine, Neuron, Stroke, Ambient occlusion, Biomedical sciences, MBA, MD, Physician, Professor, Face, Medical device, Cheetah, Walrus, Medicine, Hippopotamus, Radiology, Neurosurgery

FREMONT, Calif., Dec. 12, 2023 /PRNewswire/ -- Q'Apel Medical Inc. launches a new generation aspiration technology - the 072 Hippo Aspiration System, developed for patients suffering from a stroke due to a large vessel occlusion.

Key Points: 
  • FREMONT, Calif., Dec. 12, 2023 /PRNewswire/ -- Q'Apel Medical Inc. launches a new generation aspiration technology - the 072 Hippo Aspiration System, developed for patients suffering from a stroke due to a large vessel occlusion.
  • The recent FDA cleared stroke system, comprised of the 072 Hippo Aspiration Catheter and its Cheetah companion, represents a paradigm shift in emergent neurovascular intervention.
  • "Our initial experience with the Hippo Aspiration System really demonstrated outstanding system performance.
  • The Hippo Aspiration System also grants us the ability to offer physicians a complete stroke procedure.

Colombia Set to Cull Wild Hippo Herd, Sparks Eco-Revolution: BloodSweaT™ Seeks to Save Hippos with Humane Relocation and Inaugural Products

Retrieved on: 
Monday, November 20, 2023
Sleep, Pepe, Waste, Otter, Collection, HIT, USDA, Wildlife, CAP, Hacienda Nápoles, Skin, USAF, Hippopotamus, Infection, Heart, Ecosystem, Animal, Social media, CPR, Breeding, Sterilization, Magdalena River, Mother, Atmosphere, Water, Growth, Turtle, Parent, News, Disability, Bird, Life, Drug, Poultry farming, MIAMI, Lotion

MIAMI, Nov. 20, 2023 /PRNewswire/ -- Humanitarian organization, BloodSweaT officially announced its launch to address the ongoing Colombian hippo crisis and imminent herd culling*, tackling the eco-challenge with relocation efforts while exploring the unique properties of naturally made hippo "blood sweat" in innovative new products.

Key Points: 
  • "I toured the most diverse ecosystem on our planet and we talked to the folks who live around the waterways and towns where the hippos roam," explained Dziadik.
  • "I entered the Magdalena River and encountered a large wild male hippo – I named him Hugo.
  • But when this happens in a river, they occasionally float off while they sleep, widening their range to unknown locations downstream."
  • The rapidly breeding populations of hippos in the area have risen to unknown numbers and locations.

Ikena Oncology Shares Initial Positive and Differentiated Dose Escalation Data from IK-930 Phase I Trial and Reports Third Quarter 2023 Financial Results

Retrieved on: 
Thursday, November 9, 2023
EGFR, Research, NSCLC, Fatigue, Epithelioid hemangioendothelioma, TEAD, Diarrhea, Physician, Hippopotamus, Weight gain, Meningioma, Liver, Quarter, Wind, Additive effect, Nausea, NF2, Quality of life, Growth, Disease, Caregiver, Clinical trial, Neoplasm, TEAD1, Biology, DLT, Cancer, Partnership, Collaboration, Mesothelioma, Liver failure, Nephrotoxicity, Blood, Pain, Patient, VGLL4, TAZ, EHE, Therapeutic index, Proteinuria, Pharmaceutical industry, Vaccine, Cryptocurrency, Pionýr

BOSTON, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced financial results for the quarter ended September 30, 2023, and provided a corporate update. The Company also shared initial data from twenty-six (26) patients treated in the ongoing dose escalation portion of the Phase I clinical trial of IK-930, a novel, oral, potent, and highly selective Hippo pathway inhibitor.

Key Points: 
  • The Company also shared initial data from twenty-six (26) patients treated in the ongoing dose escalation portion of the Phase I clinical trial of IK-930, a novel, oral, potent, and highly selective Hippo pathway inhibitor.
  • “This early look at the IK-930 dose escalation data strongly supports our differentiated approach to targeting the Hippo pathway.
  • Importantly, following the target biology and initially focusing on EHE has allowed us to observe clinical activity of IK-930 early in our dose escalation.
  • Twenty-six patients with a range of solid tumors were treated in the dose escalation portion of the study as of October 31, 2023.

Concerned Shareholder Group Urges the Board of Directors of Hippo Holdings Inc. to Initiate a Strategic Review Following a Period of Significant Value Destruction

Retrieved on: 
Thursday, September 14, 2023
Professional Services, Insurance, Finance, Uncertainty, Chairperson, Indian psychology, EBITDA, Risk, Hippopotamus, HIPO, NYSE, Management

Hippo is now a micro-cap stock that trades at a roughly 50% discount to book value.

Key Points: 
  • Hippo is now a micro-cap stock that trades at a roughly 50% discount to book value.
  • We believe the Board must immediately embrace its fiduciary duty to preserve shareholder value while navigating a highly regulated industry.
  • Additionally, the Company should take immediate steps to enhance its financial disclosures so that shareholders can hold the Board and management accountable.
  • The Concerned Shareholder Group will seek to hold you accountable if no value-enhancing actions are taken.

Hippo Names Peter Piotrowski Chief Claims Officer

Retrieved on: 
Thursday, August 10, 2023
Residential Building & Real Estate, Construction & Property, Professional Services, Insurance, Hanover Insurance, Chubb, NYSE, AIG, Vault, Management, Hippopotamus

Hippo (NYSE: HIPO), the home insurance group focused on proactive home protection, today named Peter Piotrowski, Chief Claims Officer.

Key Points: 
  • Hippo (NYSE: HIPO), the home insurance group focused on proactive home protection, today named Peter Piotrowski, Chief Claims Officer.
  • Piotrowski will lead claims for Hippo Insurance Services after serving as Chief Claims Officer at Vault for the last six years, and in executive roles at The Hanover Insurance Group, AIG and Chubb.
  • With more than 35 years of experience, Piotrowski will oversee Hippo’s claims services to provide its customers with a technology-enabled, industry-leading claims experience.
  • He will serve as a key member of Hippo's executive team and report to Chief Underwriting Officer Chris Donahue.

Ikena Oncology Reports Second Quarter 2023 Financial Results and Corporate Update

Retrieved on: 
Thursday, August 10, 2023
Insurance, Therapeutic index, Clinical trial, Research, MEK, Doctor of Philosophy, Acquisition, Patient, Investment, EGFR, Collaboration, Hippopotamus, IND, Pharmaceutical industry, Cryptocurrency

BOSTON, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced financial results for the quarter ended June 30, 2023. The Company also provided pipeline and corporate updates from the quarter and recent months.

Key Points: 
  • BOSTON, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced financial results for the quarter ended June 30, 2023.
  • The Company also provided pipeline and corporate updates from the quarter and recent months.
  • “It has been a busy time at Ikena, with new high-quality investors and peers sharing our confidence in our targeted oncology pipeline translating to important corporate milestones.
  • Research and development expenses were $15.2 million and $15.5 million for the three months ended June 30, 2023 and 2022, respectively.

Ikena Oncology Acquires Pionyr Immunotherapeutics in All-Stock Transaction

Retrieved on: 
Monday, August 7, 2023
Gilead Sciences, Acquisition, Investment, CVR, Hippopotamus, New Enterprise Associates, IND, Security (finance), Pharmaceutical industry, Bank, Pionýr

BOSTON and SOUTH SAN FRANCISCO, Calif., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, and Pionyr Immunotherapeutics, Inc. (Pionyr), a privately-held, clinical-stage biotechnology company, today announced the closing of Ikena’s acquisition of Pionyr in an all-stock transaction. Ikena acquired all of Pionyr’s assets, including approximately $43 million in net cash, in exchange for shares of IKNA stock, in a combination of common stock and non-voting convertible preferred stock priced at $7.15 per share.

Key Points: 
  • BOSTON and SOUTH SAN FRANCISCO, Calif., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, and Pionyr Immunotherapeutics, Inc. (Pionyr), a privately-held, clinical-stage biotechnology company, today announced the closing of Ikena’s acquisition of Pionyr in an all-stock transaction.
  • “Ikena has made incredible strides this year, and we are glad to welcome the Pionyr shareholders to the Ikena team as we head into a pivotal time for our targeted oncology programs,” said Mark Manfredi, Ph.D., Chief Executive Officer of Ikena.
  • The new Ikena shareholders include New Enterprise Associates, SV Health Investors, Sofinnova Investments, Vida Ventures, and Gilead Sciences.
  • “On behalf of our investors, board of directors, and the Pionyr executive team, I want to thank and congratulate the entire Pionyr team for their efforts.”
    Further details on the transaction are described below.